Qiagen NV

QGEN

Company Profile

  • Business description

    Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

  • Contact

    Hulsterweg 82
    VenloLI5912 PL
    NLD

    T: +31 773556600

    E: [email protected]

    https://www.qiagen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    5,700

Stocks News & Analysis

stocks

WiseTech result disappoints, but the future looks bright

Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
stocks

WOW earnings: Woolworths losing market share, but will catch up to Coles

Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.
stocks

Chart of the Week: Largest share price falls during earnings

Opportunities arise when the market overreacts, and good quality companies are mispriced.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,241.100.50-0.01%
CAC 407,817.5173.580.95%
DAX 4024,108.3162.100.26%
Dow JONES (US)45,565.23147.160.32%
FTSE 1009,236.3619.14-0.21%
HKSE24,998.82202.94-0.81%
NASDAQ21,590.1445.870.21%
Nikkei 22542,828.79308.520.73%
NZX 50 Index12,903.0841.240.32%
S&P 5006,481.4015.460.24%
S&P/ASX 2008,980.009.500.11%
SSE Composite Index3,843.6043.251.14%

Market Movers